263P - Management of stage I testicular seminoma: A retrospective study from Institute of Oncology “Ion Chiricuta”, Romania

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Germ Cell Tumours
Presenter Nicoleta Antone
Citation Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524
Authors N.Z. Antone1, E. Olteanu2, N. Todor1, C.L. Cebotaru1
  • 1Radiotherapy, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO
  • 2Oncopediatry, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO



A retrospective study that evaluated treatment outcomes and risk factors for stage I testicular seminoma treated at Institute of Oncology Ion Chiricuta, Romania.


Our series included 150 patients, age between 19 and 78 years (median age-36 years) stage I pure seminoma assessed between January 1982 and January 2009 and treated at Institute of Oncology “Ion Chiricuta”, Romania. For inclusion in the final analysis patients had to fulfill the following inclusion criteria: male, age minimum 14 years old, confirmed GCT either by histology and/or serum tumor markers and sufficient follow-up 135.8 months (range minimum 3 - maximum 233 months). The adjuvant setting consisted of one cycle Carboplatin AUC 7(area under curve 7) or two cycles Carboplatin AUC 6 (area under curve 6) or radiotherapy or surveillance.


At the time of the analysis the overall survival at 10 years was 94% (CI: 88%-97%). One hundred seminoma patients (80%) had no relapse, metastatic relapse was observed in 6 patients (4%), pelvic or lomboaortic lymph nodes were present in 21 patients (14%), metastatic and node relapse in 2 patients (1,33%) and seric relapse in 1 patient(0,67%). The following risk factors for relapse were assessed: age at presentation (<40 vs. >40 years, p = 0.03), ECOG performance status ( 0-91%, 1-62%, 2-25%, p < 0.01) and stage at initial presentation (IA-63%, IB-65%, IS-90%, p < 0.03).Chemotherapy toxicity was moderate, main toxicity for Carboplatin was thrombocytopenia (6,67%), anemia(3,7%), leucopenia (3,33%), and nausea and vomiting (3,33%).


The prognostic values for patients with stage I pure seminoma in our series was excellent. The rate of curability for adjuvant setting was high, the overall survival at 10 years with adjuvant chemotherapy was 98%, with adjuvant radiotherapy 93% and overall survival for patients treated with orchiectomy and managed by surveillance was 37%. We conclude that treatment decisions regarding stage I testicular seminoma should rest on late toxicities, morbidity and patient preference.

Clinical trial identification


All authors have declared no conflicts of interest.